Table 42Adverse effects for single auto HSCT and comparison (conventional chemotherapy +/- radiation) groups

OutcomeIntervention (HSCT [%])Comparator (Chemo [%])Study
Treatment-related mortality12%Not applicableMeyers, USA, 2001364
18%Not applicableBurdach, Germany and Austria, 2000353
5%Not applicableDrabko, Poland, 2005356
13%Not applicableOzkaynak, USA, 1998367
18%Not applicableYaniv, Israel, 2004371
2%*Not applicableLadenstein,Austria/France/UK/Switzerland/Netherl ands/Germany/Sweden, 2010375
0%Not applicableNavid, 2006365; Prete, 1998369; Burke, 2007355; Tanaka, 2002370; Pession, 1999368; Lucidarme, 1998363 Ilari, 2010374
38%Not applicableBurdach, Germany and Austria, 2010 376
Not applicable5%Bernstein, USA/Canada 2006388
Not applicable0.6%*Van Winkle, USA, 2005387
Not applicable0%Milano, Italy, 2006385
Infectious complications5% septic deathNot applicableMeyers, USA, 2001364
18% septic deathNot applicableBurdach, Germany and Austria, 2000353
5% septic deathNot applicableDrabko, Poland, 2005356
6% death due to CMV infectionNot applicableHawkins, USA, 2000359
Sepsis 28% (not leading to death)Not applicableBurke, USA, 2007355
4/24 (17%) cases of sepsisNot applicableIlari, Italy, 2010374
1/47 (2%) septic shock
1/47 (2%) fungal infection
Not applicableDiaz, Spain, 2010372
13%Not applicableBurdach, Germany and Austria, 2010 376
0%Not applicableTanaka, 2002370; Kasper, 2006360
Not applicable6/110 (5%) septic deathsBernstein, USA/Canada 2006388
Not applicable2/18 (11%) cases of sepsisMilano, Italy, 2006385
Secondary malignancies11% (MDS n=2 liposarcoma n=1)Not applicableBurdach, Germany and Austria, 2000353
0%Not applicableNavid, 2006365, Ilari, 2010374, Ladenstein, 2010375
n=1 (AML)Not applicableCosta, USA, 2008377
25%Not applicableBurdach, Germany and Austria, 2010 376
Not applicable1/110 (1%)
MDS
Bernstein, USA/Canada 2006388
Not applicable10% (MDS/AML)Bhatia, USA, 2007383
Not applicable1/1 CMLNumata, Japan, 2002382
Not applicable0%Sari, Turkey, 2010386
Not applicable1/24 (4%) AMLKushner, USA, 1995384
Long-term complications10%
n=1 died (pulmonary failure)
Not applicableKushner, USA, 2001361
n=1 dilated CMP, pulmonary HTN, renal failure, interstitial pneumoniaNot applicableLucas, USA, 2008381
n=1 short stature/growth retardation
n=5 ovarian impairment
Not applicableIlari, Italy, 2010374
Not applicable0/18 (0%)Milano, Italy, 2006385
Veno-occlusive disease10% (n=2 moderate/severe VOD)Not applicableDrabko, Poland, 2005356
6% (n=1 severe VOD)Not applicableHawkins, USA, 2000359
n=5* (grade 3 VOD)Not applicableLadenstein,Austria/France/UK/Switzerland/Netherl ands/Germany/Sweden, 2010375

AML = acute myelogenous leukemia; MDS = myelodysplastic syndrome; vod = veno-occlusive disease

*

For total population

From: Systematic Reviews

Cover of Hematopoietic Stem-Cell Transplantation in the Pediatric Population
Hematopoietic Stem-Cell Transplantation in the Pediatric Population [Internet].
Comparative Effectiveness Reviews, No. 48.
Ratko TA, Belinson SE, Brown HM, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.